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Background
Hypercholesterolaemia is a major risk factor for cardio-
vascular diseases. Treatment with HMG coenzyme A
reductase inhibitors (statins) had been proven to reduce
the risk. Due to high prevalence of hypercholesterolae-
mia, statins consumption is high. Statins available in
Malaysia include atorvastatin, lovastatin, pravastatin,
rosuvastatin, simvastatin and fluvastatin. All except one
(fluvastatin) have piled up the MOH Drug Formulary
(DF); hence the need to review the statins list. Multiattri-
bute scoring tool (MAST) which takes into consideration
all variables for rational decision making could help deci-
sion makers in reviewing the list. In this study, the six
available statins were evaluated and scored.
Materials and methods
Published literatures were studied and five sessions of
expert group discussions were conducted to build the
MAST. The attributes (and factors) identified for analysis
were efficacy (clinical efficacy, clinical end points), safety
(drug interactions, hazardous side-effects, documentation),
drug applicability (drug strength/formulation, indications,
dose frequency, side-effects, food interactions, dose adjust-
ments) and costs. The average weights assigned by group
members for efficacy, safety, drug applicability and costs
were 32.6%, 26.2%, 24.1% and 17.1% respectively. Utility
values of attributes were scored based on published
evidences or/and agreements during group discussions.
Attribute scores were summed to provide total utility
score for each statin.
Results
Atorvastatin scored the highest total utility score (TUS)
of 77.88, followed by simvastatin (75.05). Atorvastatin
and simvastatin scored consistently high even before
acquisition costs were included. Low score on side effects
for atorvastatin were compensated by higher scores on
clinical end points resulting in higher TUS for atorvasta-
tin. Pravastatin, lovastatin and rosuvastatin received TUS
of 71.95, 71.45 and 63.74 respectively. Fluvastatin had the
lowest score of 59.83.
Conclusion
The multiattribute utility scoring tool successfully sys-
tematizes decision variables to aid selection of statins for
the formulary. Based on total utility scores calculated
using the designed MAST, atorvastatin and simvastatin
should be considered as first-lines in the treatment of
hypercholesterolaemia.
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